Explore Business Standard
Targeting and stimulating underperforming neurons in the dopamine system and increasing its activity in young adulthood could help treat neuropsychiatric disorders like schizophrenia and autism with long-lasting effects, according to a new study. In mice, researchers from the University of Rochester, US, found that stimulating the neuron cells providing dopamine to the frontal cortex strengthened the circuit and rescued structural deficiencies in the brain that cause long-term symptoms. In previous studies, the research team had found this specific arm of the dopamine system to be flexible in adolescents but not in adults. In this study, published in the journal eLife, they exploited this window for plasticity in the system as an opportunity for therapeutic intervention, effects of which could affect the brain circuitry into adulthood. Essential in higher cognitive processing and decision-making, dysfunction of the dopamine system has been found to often begin in young ...
Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic product used to treat schizophrenia and in some cases to control severe nausea. The company has received nod from the US Food & Drug Administration (USFDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the Mumbai-based drug maker said in a statement. The company's product is the generic version of GlaxoSmithKline's Compazine tablets, it added. According to IQVIA sales data for the 12-month period ending January 2023, the Compazine tablets 5 mg and 10 mg achieved annual sales of around USD 26.9 million. Glenmark said its current portfolio consists of 182 products authorised for distribution in the US marketplace and 46 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA. PTI MSS.